The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease
Abstract
High dosages of a combination of alpha-tocopherol and ascorbate were administered to patients with early Parkinson's disease as an open-labeled trial and pilot study to test the endogenous toxic hypothesis of the etiology of Parkinson's disease. Patients receiving concomitant amantadine and anticholinergics were allowed to participate, but those receiving levodopa or dopamine agonists were not. The study was begun prior to the availability of deprenyl. The primary end point of the trial was progression of the disease until patients needed treatment with levodopa or a dopamine agonist. The time when levodopa became necessary in the treated patients was compared to another group of patients followed elsewhere who did not receive antioxidants. The time when levodopa became necessary was extended by 2.5 years in the group receiving alpha-tocopherol and ascorbate. Results of this pilot study suggest that the progression of Parkinson's disease may be slowed by administration of these antioxidants. Controlled clinical trials using double-blind randomization techniques are required to confirm these results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concurrent intake of high doses of vitamin C and vitamin E (α-tocopherol) delayed the onset of treatment for more than 2 years in newly diagnosed PD patients (Fahn 1992).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Fahn 1992
Citations
Cites
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,925
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 912
Third symposium on Parkinson's disease
Tucker, J. S. (1970) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(70)90108-2 · Cited by 416
DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
(1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460028009 · Cited by 357
Dg, G. (1984) · PubMed · Cited by 292
Possible role of neuromelanin in the pathogenesis of Parkinson's disease
Mann, D. M. A., & Yates, P. O. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90074-x · Cited by 211
Monoamines, noyaux gris centraux et syndrome de Parkinson
Stern, G. M. (1975) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(75)90147-1 · Cited by 134
Vatassery, G. T., Brin, M. F., Fahn, S., Kayden, H. J., & Traber, M. G. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01083.x · Cited by 106
Self-citationShould Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment
Fahn, S., & Bressman, S. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046412 · Cited by 101
Self-citationAn open trial of high-dosage antioxidants in early Parkinson's disease
Fahn, S. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/53.1.380s · Cited by 90
Self-citationConsiderations in the management of parkinsonism
Fahn, S., & Calne, D. B. (1978) · Neurology · doi:10.1212/wnl.28.1.5 · Cited by 88
Self-citationFree Radical Protection: Why Vitamin E, Not Vitamin C, β‐Carotene or Glutathione?
Wilson, R. L. (1983) · Novartis Foundation symposium · doi:10.1002/9780470720820.ch3 · Cited by 71
Fahn, S. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb14919.x · Cited by 60
Self-citation
Flagged first, then by citations
1 of the 14 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Cohen, 1983, Neural Transm, 19, 89
- Graham, 1984, Neurotoxicology, 5, 83
- Olanow, 1990, Neurology, 40, 32
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
Oxidative processes and antioxidative defense mechanisms in the aging brain 1
Reiter, R. J. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737461 · Cited by 801
Oxidative Stress and Antioxidants in Neurodegenerative Disorders
Olufunmilayo, E. O., Gerke-Duncan, M. B., & Holsinger, R. M. D. (2023) · Antioxidants · doi:10.3390/antiox12020517 · Cited by 752
Metadata
- Authors
- Fahn, S.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Fahn, Stanley
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1992
- Volume
- 32
- Issue
- S1
- Pages
- S128-S132
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2112404451
- Cited by
- 211
- References
- 14
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 3 · 2014: 9 · 2013: 4 · 2012: 3
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- Parkinson's disease, alpha-tocopherol, vitamin C, antioxidants, disease progression, early-stage Parkinson's disease, amantadine, anticholinergic agents
- MeSH terms
- Adult, Aged, Ascorbic Acid, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Research Design, Vitamin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review